P.063 Durability over time of strategies to reduce door-to-needle times in thrombolysis of acute ischaemic stroke
نویسندگان
چکیده
منابع مشابه
Reducing door to needle time for stroke thrombolysis
Better outcomes are obtained with stroke thrombolysis the more rapidly it is given, both in terms of the patient's level of functional ability and also mortality. Current UK performance targets (outside London) aim for a time of 45 minutes or less. Thrombolysis pathways involve multidisciplinary working across departmental boundaries as well as senior level decision making. Our system used tele...
متن کاملImproving Door-to-Needle Times for Acute Ischemic Stroke
Faster treatment with intravenous alteplase (tissue-type plasminogen activator) results in better outcomes. Although the benchmark door-to-needle time (DTN) has been set at 60 minutes, many centers have been able to exceed this benchmark with median times from 20 to 51 minutes. These local efforts have been supported by national and international efforts to reduce DTN time. For example, the Ame...
متن کاملEmergency department thrombolysis improves door to needle times.
OBJECTIVE To identify the effect on door to needle (DTN) time of moving the site of thrombolysis delivery from the coronary care unit (CCU) to the emergency department (ED). To ascertain if moving the site of thrombolysis enables appropriate use of thrombolysis. DESIGN Prospective cohort study. SETTING CCU and ED of a 450 bed Scottish district general hospital without on-site primary angiop...
متن کاملImproving door to needle times with nurse initiated thrombolysis.
OBJECTIVE To evaluate the effect of nurse initiated thrombolysis on door to needle time (the interval between arriving at the hospital and starting thrombolytic treatment) in patients with acute myocardial infarction. DESIGN Comparison of door to needle times before and after the employment of nurses trained and approved to initiate thrombolysis without prescription by a doctor but with a pro...
متن کاملSymptom-to-needle Times in Acute Ischemic Stroke and Its Prehospital Related Factors
Background: Intravenous (IV) recombinant tissue Plasminogen Activator (rtPA) (IV-rtPA) is the only FDA-approved pharmacological therapy for treatment in acute ischemic stroke and the administration of IV-rtPA is crucially time-dependent. Objectives: This study aimed to evaluate symptom-to-needle time and factors associated with the prehospital delay in patients with acute ischemic stroke refer...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
سال: 2016
ISSN: 0317-1671,2057-0155
DOI: 10.1017/cjn.2016.167